Could a cancer drug shield young transplant patients from a deadly complication?

NCT ID NCT03842696

Ongoing Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers. Researchers are first finding the best dose of vorinostat, then checking if it lowers the rate of moderate-to-severe GVHD within 100 days after transplant. The trial enrolled 43 participants across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vorinostat
What this could lead to: If it works, this could point toward a safer way to prevent graft-versus-host disease in young transplant patients, reducing a major complication.
What could go wrong: This is an early phase 1/2 trial with only 43 participants, so results may not apply broadly. Vorinostat may not reduce GVHD or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA IN REMISSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelogenous leukemia, BCR-ABL1 positive diffuse large B-cell lymphoma follicular lymphoma hematologic disorder leukemia, myeloid, accelerated-phase Leukemia, Myeloid, Chronic-Phase mantle cell lymphoma myelodysplastic syndrome Myelodysplastic Syndromes non-Hodgkin lymphoma graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA IN REMISSION CHRONIC MYELOGENOUS LEUKEMIA - CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA, BLASTIC PHASE DIFFUSE LARGE B-CELL LYMPHOMA FOLLICULAR LYMPHOMA GRAFT VS HOST DISEASE GRAFT-VERSUS-HOST DISEASE HEMATOLOGIC DISEASES MANTLE CELL LYMPHOMA MYELODYSPLASTIC SYNDROMES NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Emory University

Atlanta, Georgia, 30322, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, 46202, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
University of Colorado

Aurora, Colorado, 80045, United States
University of Michigan Health System

Ann Arbor, Michigan, 48109, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.